Virus Like Particles
Virus-like particles (VLPs) are self-assembled protein structures that resemble viruses but lack infectious genetic material. They mimic the structural and antigenic properties of viruses, making them powerful tools in biomedicine and biotechnology.
Structure
VLPs are composed of viral capsid proteins that self-assemble into highly ordered, repetitive structures. These particles can be icosahedral, helical, or complex, depending on the virus of origin. The absence of nucleic acids renders VLPs non-replicative and safe for use in various applications.
Production
VLPs can be expressed in multiple systems, including:
- Bacteria (e.g., E. coli): High yield but limited post-translational modifications.
- Yeast (e.g., Pichia pastoris): Efficient glycosylation capabilities.
- Insect cells (using baculovirus): Suitable for complex VLPs.
- Mammalian cells: Ideal for human-specific modifications.
Applications
- Vaccines
- Prophylactic vaccines: VLP-based vaccines like those for human papillomavirus (HPV, Gardasil, Cervarix) and hepatitis B virus (HBV) are commercially successful.
- Therapeutic vaccines: Investigated for cancer and chronic infections, leveraging their ability to elicit strong immune responses.
- Drug Delivery
- VLPs can encapsulate drugs, nucleic acids, or imaging agents for targeted delivery. Their nanoscale size and modifiable surface make them versatile carriers.
- Diagnostics
- VLPs serve as scaffolds for displaying antigens, facilitating the development of diagnostic assays for serological studies and rapid pathogen detection.
- Gene Therapy
- Engineered VLPs are explored as vehicles for delivering therapeutic nucleic acids, such as siRNA and CRISPR/Cas9 components.
- Nanotechnology
- VLPs are used in nanomaterial fabrication, biosensors, and enzymatic catalysis due to their uniform size and ability to functionalize.
Virus-like particles are a cornerstone of modern biotechnology, with widespread applications in vaccine development, drug delivery, and diagnostics. Ongoing advancements in synthetic biology and structural engineering are expected to unlock their full potential.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|